文献速递免疫规划慢病防控与筛查传染病防控与疫情报告

HIV阳性男男性行为者肛门癌预防中的辅助HPV疫苗接种:时机已到

Adjuvant HPV vaccination for anal cancer prevention in HIV-positive men who have sex with men: The time is now.
PubMed 文献 · Vaccine · 2017-08-12

该研究用Markov队列模型评估27岁及以上HIV感染男男性行为者HSIL治疗后辅助四价HPV疫苗接种的成本效果。增量成本效果比为每质量调整生命年71937美元,在支付意愿阈值每质量调整生命年100000美元下「治疗加接种」最具成本效果。辅助qHPV疫苗效力相关的期望部分完美信息价值为0,提示额外效力数据不会改变该政策结论。

要点

  • 在支付意愿阈值每QALY 100000美元下,「治疗加接种」是27岁及以上HIV感染MSM最具成本效果的HSIL管理策略。
  • 辅助qHPV疫苗效力相关的期望部分完美信息价值为0,未来效力研究数据不会改变「治疗加接种」具成本效果的结论。
  • 成本效果比与期望完美信息价值均对HSIL治疗依从性敏感。

核心结论

  • 27岁及以上HIV感染MSM HSIL治疗后辅助qHPV疫苗接种可能具成本效果,可考虑作为减轻该高危人群肛门癌负担的潜在策略。

研究设计与样本

  • 研究建立Markov状态转移队列模型,评估27岁及以上HIV感染MSM HSIL治疗后辅助HPV疫苗接种的成本效果。
  • 研究先估计成本效果,再进行价值信息分析,估计期望完美信息价值(EVPI)与期望部分完美信息价值(EVPPI)。

主要发现

  • 「治疗加接种」策略的增量成本效果比(ICER)为每QALY 71937美元,在支付意愿阈值每QALY 100000美元下为最具成本效果的HSIL管理策略。
  • 与辅助qHPV疫苗效力(以减少HSIL复发风险比表示)相关的EVPPI为0美元。
  • ICER与EVPI均对HSIL治疗依从性敏感。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Outcomes of treating high-grade squamous intraepithelial lesions (HSIL), a precursor to anal cancer, remain uncertain. Emerging evidence shows that post HSIL treatment adjuvant quadrivalent human papillomavirus (qHPV) vaccination improves the effectiveness of treatment. However, no recommendations exist regarding the use of qHPV vaccine as an adjuvant form of therapy. Our objective was to determine whether post-treatment adjuvant vaccination should be adopted in HIV-infected MSM (individuals at highest risk for anal cancer) on the basis of cost-effectiveness determined using existing evidence or whether future research is needed. METHODS: We developed a Markov (state-transition) cohort model to assess the cost-effectiveness of post-treatment adjuvant HPV vaccination of 27years or older HIV-infected MSM. We first estimated cost-effectiveness and then performed value-of-information (VOI) analysis to determine whether future research is required by estimating the expected value of perfect information (EVPI). We also estimated expected value of partial perfect information (EVPPI) to determine what new evidences should have highest priority. RESULTS: With the incremental cost-effectiveness ratio (ICER) of $71,937/QALY, "treatment plus vaccination" was the most cost-effective HSIL management strategy using the willingness-to-pay threshold of 100,000/QALY. We found that population-level EVPI for conducting future clinical research evaluating HSIL management approaches was US$12 million (range $6-$20 million). The EVPPI associated with adjuvant qHPV vaccination efficacy estimated in terms of hazards of decreasing HSIL recurrence was $0 implying that additional data from a future study evaluating efficacy of adjuvant qHPV vaccination will not change our policy conclusion that "treatment plus vaccination" was cost-effective. Both the ICER and EVPI were sensitive to HSIL treatment compliance. CONCLUSION: Post-treatment adjuvant qHPV vaccination in HIV-infected MSM aged 27 or above is likely to be cost-effective. Use of adjuvant qHPV vaccination could be considered as a potential strategy to reduce rising anal cancer burden among these high-risk individuals.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Deshmukh AA, Cantor SB, Fenwick E, et al. Adjuvant HPV vaccination for anal cancer prevention in HIV-positive men who have sex with men: The time is now. Vaccine. 2017. PMID: 28807605. doi:10.1016/j.vaccine.2017.08.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。